You are here
The selection of available analgesic drugs has improved in recent years; however, standard treatment options for management of chronic cancer pain, post-surgical pain, and neuropathic pain remain less than optimal.
- Up to 70% of cancer patients cannot take oral medications
- 40-50% of cancer patients do not receive adequate pain relief
- Up to 75% of post-operative surgery patients do not receive adequate pain relief
- Opioids and NSAIDS (non-steroidal anti-inflammatory drugs) are associated with adverse effects, such as constipation, respiratory depression, cognitive impairment, and GI bleeding, which limit their use.
In the area of analgesia, Angiochem is developing a promising neurotensin derivative, based on its platform technology, for the management of moderate to severe post-surgical and cancer pain.
Due to neurotensin’s ineffective penetration through the blood-brain barrier (BBB), its potential as a therapeutic agent has been difficult to realize. ANG2002 is a new chemical entity formed by the conjugation of the peptide Angiopep-2 and neurotensin. The analgesic effect of ANG2002 shows great potential as a first-in-class analgesic in many widely accepted preclinical models of acute pain, inflammatory pain, post-operative pain, cancer pain, and neuropathic pain. In all those models, the activity was equal or superior to morphine and gabapentin (Demeule et al., 2014).
Overall study results of ANG2002 further validate the potential of the Angiochem technology for the development of effective neurotherapeutics.